Is Truseltiq Approved for FGFR2-Positive Cancers?
Truseltiq (futibatinib) is FDA-approved for adults with unresectable, locally advanced, or metastatic cholangiocarcinoma (bile duct cancer) with FGFR2 fusions or other rearrangements, following prior systemic therapy.[1] These genetic alterations make tumors FGFR2-positive, and Truseltiq targets FGFR2 specifically, blocking downstream signaling to inhibit cancer growth.[2]
How Does Truseltiq Work Against FGFR2?
Futibatinib is a selective, irreversible FGFR inhibitor that binds covalently to FGFR2, FGFR3, and FGFR4. In FGFR2-altered cholangiocarcinoma, fusions like FGFR2-BICC1 drive tumor proliferation; Truseltiq disrupts this pathway, leading to tumor regression in responsive patients.[3] Clinical trials showed 42% objective response rate (ORR) in FGFR2 fusion-positive cases, with median duration of 9.7 months.[1]
Which Specific Cancers and Mutations Qualify?
Approval covers only FGFR2 fusion/rearrangement-positive intrahepatic or extrahepatic cholangiocarcinoma confirmed by FDA-approved tests like FoundationOne CDx.[1] It does not extend to FGFR2 mutations (e.g., point mutations) without fusions, other solid tumors, or FGFR1/3-driven cancers unless in trials.
What Trial Data Supports This Use?
FOENIX-CCA2 phase 2/3 trial (n=103 FGFR2 fusion-positive patients) reported 41.7% ORR, 9.7-month median duration, and 21.7-month median progression-free survival versus 3.7 months for chemotherapy.[4] Real-world data aligns, with responses in 30-50% of pretreated patients.[5]
Are There Ongoing Trials for Other FGFR2-Positive Cancers?
Yes, Truseltiq is in phase 2/3 trials for FGFR2-altered gastric cancer (FOENIX-CCA3), urothelial carcinoma, and other solid tumors.[6] Early data show activity in gastric (ORR ~30%) and bladder cancers with FGFR2/3 alterations, but no broad approvals yet.
Common Side Effects in FGFR2 Patients
Hyperphosphatemia (78%, often severe) requires phosphate binders and monitoring. Other issues include dry mouth (78%), nail toxicity (64%), diarrhea (57%), and fatigue (52%). Dose adjustments manage most cases; discontinuation rate was 11%.[1][4]
How Does It Compare to Other FGFR Inhibitors?
| Drug | Target Cancers | FGFR Selectivity | ORR in FGFR2 Cholangiocarcinoma |
|------|----------------|------------------|--------------------------------|
| Truseltiq (futibatinib) | FGFR2 fusion cholangiocarcinoma | FGFR1-4 (covalent) | 42% [1] |
| Pemazyre (pemigatinib) | FGFR2 fusion/broad cholangiocarcinoma | FGFR1-3 | 36% [7] |
| Lytgobi (erdafitinib) | FGFR-altered urothelial (not primary for FGFR2) | pan-FGFR | N/A for cholangiocarcinoma [8] |
Truseltiq shows higher responses in fusions but more hyperphosphatemia.[9]
Patent and Availability Details
Takeda holds U.S. patents on futibatinib through 2037-2041 (composition, methods of use); no generic challenges listed yet.[10] Available as 4mg tablets; list price ~$25,000/month (U.S.).[11]
[1]: FDA Label for Truseltiq
[2]: NEJM: Futibatinib Mechanism
[3]: Nature Reviews: FGFR Inhibitors
[4]: Lancet Oncology: FOENIX-CCA2
[5]: JCO Precision Oncology: Real-World
[6]: ClinicalTrials.gov: Futibatinib Trials
[7]: FDA Label for Pemazyre
[8]: FDA Label for Lytgobi
[9]: ESMO: Comparative Review
[10]: DrugPatentWatch: Futibatinib Patents
[11]: GoodRx: Truseltiq Pricing